Chilean experience using "Theranostics" for treating metastatic neuroendocrine tumors with [177Lu]Lu DOTA-TATE

<p>Introduction: Well-differentiated, Neuroendocrine Tumors (NET) are highly heterogenic and slow-growing pathologies, characterized by unspecific symptomatology and elevated expression of somatostatin receptors (SSTR). Despite the high incidence of NETs, several patients are diagnosed in adva...

Full description

Saved in:
Bibliographic Details
Main Authors: Horacio Amaral (Author), Rossana Pruzzo (Author), René Fernández (Author), Vasko Kramer (Author), Cristian Soza-Ried (Author), Irene Coudeu (Author)
Format: Book
Published: Archives of Clinical Gastroenterology - Peertechz Publications, 2020-05-27.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 peertech__10_17352_2455-2283_000076
042 |a dc 
100 1 0 |a Horacio Amaral  |e author 
700 1 0 |a  Rossana Pruzzo  |e author 
700 1 0 |a  René Fernández  |e author 
700 1 0 |a  Vasko Kramer  |e author 
700 1 0 |a  Cristian Soza-Ried  |e author 
700 1 0 |a Irene Coudeu  |e author 
245 0 0 |a Chilean experience using "Theranostics" for treating metastatic neuroendocrine tumors with [177Lu]Lu DOTA-TATE 
260 |b Archives of Clinical Gastroenterology - Peertechz Publications,   |c 2020-05-27. 
520 |a <p>Introduction: Well-differentiated, Neuroendocrine Tumors (NET) are highly heterogenic and slow-growing pathologies, characterized by unspecific symptomatology and elevated expression of somatostatin receptors (SSTR). Despite the high incidence of NETs, several patients are diagnosed in advance stages of the disease when surgery is insufficient to treat the pathology. Peptide receptor radionuclide therapy (PRRT) has emerged as a new state-of-the-art treatment for NET-patients in advanced stages. </p><p>Results: In this retrospective study, between 2004 and 2018 a total of 66 patients with advanced-stage-NETs, refractory to other therapies, were treated with [177Lu]Lu DOTA TATE.  At the end of the study, 56.1% of the patients were alive and the median overall survival for all patients in the study was 86.3 months. Patients that received doses ≥ 22.2 GBq showed increased overall survival (OS) in comparison with patients that received doses < 22.2 GBq (HR, 0.168; 95%CI 0.12- 0.99; p<0.001), adjusted by gender. Likewise, patients that received doses ≥29.6 GBq had an increased OS (HR, 0.42; 95%CI 0.19-0.94, p<0.05). </p><p>Conclusion: Although several studies have shown that PRRT is an effective alternative for advanced NET, patients in South America have no regular access to PRRT. Our study proves that [177Lu]Lu-DOTA-TATE effectively increases the survival of patients with metastatic NET and provides an excellent alternative in terms of cost-efficiency for South American countries. </p> 
540 |a Copyright © Horacio Amaral et al. 
546 |a en 
655 7 |a Research Article  |2 local 
856 4 1 |u https://doi.org/10.17352/2455-2283.000076  |z Connect to this object online.